Phathom Pharmaceuticals, Inc. Shareholders Equity (Total)

Shareholders Equity (Total) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity (Total) growth rates and interactive chart. Shareholder equity, also referred to as shareholders' equity and stockholders' equity, it a corporation's owners' residual claim after debts have been paid. Equity is equal to a firm's total assets minus its total liabilities. It is found on a company's balance sheet and it's the total equity available to common shareholders (after accounting for preferred equity). Also called book value or net book value.

Highlights and Quick Summary

  • Shareholders Equity (Total) for the quarter ending September 29, 2021 was $103 Million (a -21.68% decrease compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity (Total) decreased by -46.73%
  • Annual Shareholders Equity (Total) for 2020 was $194 Million (a -14.78% decrease from previous year)
  • Annual Shareholders Equity (Total) for 2019 was $228 Million (a -17825.89% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity (Total) of Phathom Pharmaceuticals, Inc.

Most recent Shareholders Equity (Total)of PHAT including historical data for past 10 years.

Interactive Chart of Shareholders Equity (Total) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Shareholders Equity (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $103.48 $132.13 $164.34
2020 $194.27 $156.39 $188.42 $208.7 $194.27
2019 $227.96 $-152.46 $0.0 $0.0 $227.96
2018 $-1.29 $0.0 $-1.29

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.